A major obstacle to control cancer growth and metastasis in patients is the widespread inappropriate use of anticancer drugs. As increasing numbers and types of anticancer drugs have been developed, clinicians become more and more likely to misuse them in their practice. We have known that cancers are different etiological diseases with the same pathologic characteristics of unlimited growths. With this type of heterogeneous characters, it means responses to same anticancer drugs can be various from patient to patient even though they all develop from same organs of humans, or even represent with same histological tissues or phenotype. Owing to all these reasons, individualized cancer chemotherapy will be a future trend to improve the anticancer drug applications in clinics. In this article, we will document, review, discuss and highlight this issue.

Biography

LU Da-Yong, oc/professor; ad/1288 Shangda Rd, 95-202, Shanghai200444, PR China; ed/ph D Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 2005, MS, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 1986, BS, Shanghai Medical University (Now Fudan University affiliated), 1982; Now School of Life Sciences, Shanghai University, Shanghai200444, PR China. Undergo the studies of cancer pathology, biochemistry pharmacology and clinical therapeutics from 1982 and some hypotheses in AIDS and neural science in 2007. More than 20 scientific articles have been published in international journals.